Ritualistic Chewing Behavior induced by mCPP in the rat is an animal model of Obsessive Compulsive Disorder

Pharmacology Biochemistry and Behavior

Volumn 104, Issue 1, 2013, Pages 119-124

  Kreiss, Deborah S ^a,b   Coffman, Catherine F ^a   Fiacco, Nicholas R ^a   Granger, Jason C ^a   Helton, Bernadette M ^a   Jackson, Jennifer C ^a   Kim, Leonid V ^a   Mistry, Rishi S ^a   Mizer, Tammie M ^a   Palmer, Lolita V ^a   Vacca, Jay A ^a   Winkler, Stuart S ^a   Zimmer, Benjamin A ^a  

^a UNIVERSITY OF TENNESSEE AT CHATTANOOGA   (United States)

^b Assistant Professor in the University Libraries   (United States)

Author keywords

5 HT2C receptor; Behavior; Clomipramine; Fluvoxamine; Oral dyskinesia; Serotonin reuptake inhibitor

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; CLOMIPRAMINE; DIAZEPAM; FLUVOXAMINE; HALOPERIDOL; MIANSERIN;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; EVOKED RESPONSE; MALE; MOUTH; MOVEMENT (PHYSIOLOGY); NEUROPHYSIOLOGY; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PRESYNAPTIC POTENTIAL; PRIORITY JOURNAL; RAT; RITUALISTIC CHEWING BEHAVIOR;

ANIMALS; BEHAVIOR, ANIMAL; CLOMIPRAMINE; DIAZEPAM; DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; FLUVOXAMINE; GABA MODULATORS; HALOPERIDOL; MALE; MASTICATION; MIANSERIN; OBSESSIVE-COMPULSIVE DISORDER; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS; SEROTONIN UPTAKE INHIBITORS;

ANIMALIA; RATTUS; RODENTIA;

EID: 84873482105     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2013.01.006     Document Type: Article

References (71)

1. N. Albelda, and D. Joel Animal models of obsessive-compulsive disorder: exploring pharmacology and neural substrates Neurosci Biobehav Rev 46 2012 47 63
2. American Psychiatric Association Diagnostic and statistical manual of mental disorders, fourth edition text revision (DSM-IV-TR) 2000 American Psychiatric Press Washington, DC
3. B. Bandelow, J. Zohar, E. Hollander, S. Kasper, H.J. Möller WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision World J Biol Psychiatry 9 2008 248 312
4. G.-B. Bantsiele, D. Bentué-Ferrer, S. Saïkali, B. Laviollec, M. Bourind, and J.-M. Jean-Michel Reymanna Behavioral effects of four antidepressants on an ischemic rat model of emotional disturbances Behav Brain Res 201 2009 265 271
5. L.R. Baxter Neuroimaging studies of human anxiety disorders F.E. Bloom, D.J. Kupfer, Psychopharmacology: the fourth generation 1995 Raven Press New York 1287 1299
6. N. Bel, and F. Artigas Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei Synapse 15 1993 243 245
7. C. Benkelfat, T.E. Nordahl, W.E. Semple, A.C. King, D.L. Murphy, and R.M. Cohen Local cerebral glucose metabolic rates in obsessive-compulsive disorder: patients treated with clomipramine Arch Gen Psychiatry 47 1990 840 848
8. A. Bilkei-Gorzo, I. Gyertyan, and G. Levay mCPP-induced anxiety in the light-dark box in rats - a new method for screening anxiolytic activity Psychopharmacology 136 1998 291 298
9. G.F. Busatto, D.R. Zamignani, C.A. Buchpiguel, G.E. Garrido, M.F. Glabus, and E.T. Rocha A voxel-based investigation of regional cerebral blood flow abnormalities in obsessive-compulsive disorder using single photon emission computed tomography (SPECT) Psychiatry Res 99 2000 15 27
10. F. Catapano, F. Perris, M. Masella, F. Rossano, M. Cigliano, and L. Magliano Obsessive-compulsive disorder: a 3-year prospective follow-up study of patients treated with serotonin reuptake inhibitors OCD follow-up study Psychiatr Res 40 2006 502 510
11. Clomipramine Collaborative Group Clomipramine in the treatment of patients with obsessive-compulsive disorder Arch Gen Psychiatry 48 1991 730 738
12. P.D. De Deurwaerdere, and M.-F. Chesselet Nigrostriatal lesions alter oral dyskinesia and c-Fos expression induced by the serotonin agonist 1-(m-chlorophenyl)piperazine in adult rats J Neurosci 20 2000 5170 5178
13. 2C-induced oral dyskinesia Neuroscience 72 1996 117 128
14. S. Erzegovesi, L. Martucci, M. Henin, and L. Bellodi Low versus standard dose mCPP challenge in obsessive-compulsive patients Neuropsychopharmacology 24 2001 31 36
15. E.B. Foa, M.R. Liebowitz, M.J. Kozak, S. Davies, R. Campeas, and M.E. Franklin Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder Am J Psychiatry 162 2005 151 161
16. C.P. Freeman, M.R. Trimble, J.F. Deakin, T.M. Stokes, and J.J. Ashford Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison J Clin Psychiatry 55 1994 301 305 < http://www.ncbi.nlm.nih.gov/pubmed/8071291 >
17. L. Gong, and R.M. Kostrzewa Supersensitized oral responses to a serotonin agonist in neonatal 6-OHDA-treated rats Pharmacol Biochem Behav 41 1992 621 623
18. W.K. Goodman, L.H. Price, S.A. Rassmussen, P.L. Delgado, G.R. Heninger, and D.S. Charney Efficacy of fluvoxamine in obsessive-compulsive disorder: a double-blind comparison with placebo Arch Gen Psychiatry 46 1989 36 44
19. W.K. Goodman, L.H. Price, P.L. Delgado, J. Palumbo, J.H. Krystal, and L.M. Nagy Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine Arch Gen Psychiatry 47 1990 577 585
20. E.A. Hackler, G.H. Turner, P.J. Gresch, S. Sengupta, A.Y. Deutch, and M.J. Avison 5-Hydroxytryptamine2C receptor contribution to m- chlorophenylpiperazine and N-methyl-beta-carboline-3-carboxamide-induced anxiety-like behavior and limbic brain activation J Pharmacol Exp Ther 320 2007 1023 1029
21. R. Hoehn-Saric, P. Ninan, D.W. Black, S. Stahl, J.H. Greist, and B. Lydiard Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders Arch Gen Psychiatry 57 2000 76 82
22. E. Hollander, C. DeCaria, R. Gully, A. Nitescu, R.F. Suckow, and J.M. Gorman Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder Psychiatry Res 36 1991 1 17
23. E. Hollander, C.M. DeCaria, A. Nitescu, R. Gully, R.F. Suckow, and T.B. Cooper Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers Arch Gen Psychiatry 49 1992 21 28
24. E. Hollander, A. Kaplan, and S.M. Stahl A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder World J Biol Psychiatry 4 2003 30 34
25. E. Hollander, L.M. Koran, W.K. Goodman, J.H. Greist, P.T. Ninan, and H. Yang A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder J Clin Psychiatry 64 2003 640 647
26. H.C. Jackson, and I. Kitchen Behavioural profiles of putative 5-hydroxytryptamine receptor agonists and antagonists in developing rats Neuropharmacology 28 1989 635 642
27. M.A. Jenike, S. Hyman, L. Baer, A. Holland, W.E. Minichiello, and L. Buttolph A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory Am J Psychiatry 147 1990 1209 1215
28. D. Joel Current animal models of obsessive compulsive disorder: a critical review Prog Neuropsychopharmacol Biol Psychiatry 30 2006 374 388
29. D. Joel, E. Ben-Amir, J. Doljansky, and S. Flasisher Compulsive lever-pressing in rats is attenuated by the serotonin re-uptake inhibitors paroxetine and fluvoxamine but not by the tricyclic antidepressant desipramine or the anxiolytic diazepam Behav Pharmacol 15 2004 241 252
30. M. Karno, J.M. Golding, S.B. Sorenson, and M.A. Burnam The epidemiology of obsessive-compulsive disorder in five U.S. communities Arch Gen Psychiatry 45 1988 1094 1099
31. A.J. Kennedy, E.L. Gibson, M.T. O'Connell, and G. Curzon Effects of housing, restraint and chronic treatments with mCPP and sertraline on behavioural responses to mCPP Psychopharmacology 113 1993 262 268
32. G.A. Kennett, and G. Curzon Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors Br J Pharmacol 94 1988 137 147
33. G.A. Kennett, P. Whitton, K. Shah, and G. Curzon Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists Eur J Pharmacol 164 1989 445 454
34. G.A. Kennett, S. Lightowler, V. de Biasi, N.C. Stevens, M.D. Wood, and I.F. Tulloch Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT2C/2B receptor function Neuropharmacology 33 1994 1581 1588
35. L.M. Koran, S.L. McElroy, J.R. Davidson, S.A. Rasmussen, E. Hollander, and M.A. Jenike Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison J Clin Psychopharmacol 16 1996 121 129
36. S. Korff, and B.H. Harvey Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology Psychiatr Clin North Am 29 2006 371 390
37. D.S. Kreiss, and I. Lucki Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo J Pharmacol Exp Ther 274 1995 866 876
38. A.L. Lacerda, P. Dalgalarrondo, D. Caetano, E.E. Camargo, E.C. Etchebehere, and J.C. Soares Elevated thalamic and prefrontal regional cerebral blood flow in obsessive-compulsive disorder: a SPECT study Psychiatry Res 123 2003 125 134
39. U. Liminga, A.E. Johnson, P.E. Andren, and L.M. Gunne Modulation of oral movements by intranigral 5-hydroxytryptamine receptor agonists in the rat Pharmacol Biochem Behav 46 1993 427 433
40. I. Lucki, H.R. Ward, and A. Frazer Effect of 1-(m-chlorophenyl)piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity J Pharmacol Exp Ther 249 1989 155 164
41. J. Maj, and E. Moryl Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations J Neural Transm Gen Sect 88 1992 143 156
42. J.S. March, J. Biederman, R. Wolkow, A. Safferman, J. Mardekian, and E.H. Cook Sertraline in children and adolescents with obsessive-compulsive disorder. A multicenter randomized controlled trial J Am Med Assoc 280 1998 1752 1756
43. S.B. Math, and Y.C. Janardhan Reddy Issues in the pharmacological treatment of obsessive-compulsive disorder Int J Clin Pract 61 2007 1188 1197
44. C.J. McDougle, W.K. Goodman, J.F. Leckman, and L.H. Price The psychopharmacology of obsessive compulsive disorder. Implications for treatment and pathogenesis Psychiatr Clin North Am 16 1993 749 766
45. National Research Council Guide for care and use of laboratory animals 1996 National Academy Press Washington, DC
46. National Research Council and Institute for Laboratory Research Guidelines for the care and use of mammals in neuroscience and behavioral research 2003 National Academy of Sciences Press Washington, DC
47. J.L. Neisewander, E. Castaneda, and D.A. Davis Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats Psychopharmacology 116 1994 79 84
48. M.T. Pato, R. Zohar-Kadouch, J. Zohar, and D.L. Murphy Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder Am J Psychiatry 145 1988 1521 1525
49. M. Piccinelli, S. Pini, C. Bellantuono, and G. Wilkinson Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review Br J Psychiatry 166 1995 424 443
50. T. Pigott, and S.M. Seay A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder J Clin Psychiatry 60 1999 101 106
51. T.A. Pigott, J. Zohar, J.L. Hill, S.E. Berstein, G.N. Grover, and R.C. Zohar-Kadouch Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder Biol Psychiatry 29 1991 418 426
52. A. Plech, R. Brus, J.H. Kalbfleisch, and R.M. Kostrzewa Enhanced oral activity responses to intrastriatal SKF 38393 and m-CPP are attenuated by intrastriatal mianserin in neonatal 6-OHDA-lesioned rats Psychopharmacology 119 1995 466 473
53. S.L. Rauch, M.J. Jenike, N.A. Alpert, L. Baer, H.C. Breiter, and C.R. Savage Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography Arch Gen Psychiatry 51 1994 62 70
54. M.A. Riddle, E.A. Reeve, J.A. Yaryura-Tobias, H.M. Yang, J.L. Claghorn, and G. Gaffney Fluoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial J Am Acad Child Adolesc Psychiatry 40 2001 222 229
55. A.M. Ruscio, D.J. Stein, W.T. Chiu, and R.C. Kessler The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication Mol Psychiatry 15 2010 53 63
56. J.J. Rutter, C. Gundlah, and S.B. Auerbach Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine Neurosci Lett 171 1994 183 186
57. J. Sareen, A. Kirshner, M. Lander, K.D. Kjernisted, M.K. Eleff, and J.P. Reiss Do antipsychotics ameliorate or exacerbate Obsessive Compulsive Disorder symptoms? A systematic review J Affect Disord 82 2004 167 174
58. S. Saxena, and S.L. Rauch Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder Psychiatr Clin N Am 23 2000 563 586
59. H.B. Simpson, J.D. Huppert, E. Petkova, E.B. Foa, and M.R. Liebowitz Response versus remission in obsessive-compulsive disorder J Clin Psychiatry 67 2006 269 276
60. N. Singewald, P. Salchner, and T. Sharp Induction of c-Fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs Biol Psychiatry 53 2003 275 283
61. J.A. Stark, K.E. Davies, S.R. Williams, and S.M. Luckman Functional magnetic resonance imaging and c-Fos mapping in rats following an anorectic dose of m-chlorophenylpiperazine Neuroimage 31 2006 1228 1237
62. B.R. Stewart, P. Jenner, and C.D. Marsden Induction of purposeless chewing behaviour in rats by 5-HT agonist drugs Eur J Pharmacol 162 1989 101 107
63. E. Tsaltas, D. Kontis, S. Chrysikakou, H. Giannou, A. Biba, S. Pallidi, A. Christodoulou, A. Maillis, and A. Rabavilas Reinforced spatial alternation as an animal model of obsessive-compulsive disorder (OCD): investigation of 5-HT2C and 5-HT1D receptor involvement in OCD pathophysiology Biol Psychiatry 57 2005 1176 1185
64. R.-E. Ulloa, H. Nicolini, and A. Fernandez-Guasti Age differences in an animal model of obsessive-compulsive disorder: participation of dopamine: dopamine in an animal model of OCD Pharmacol Biochem Behav 78 2004 661 666
65. C.J. Wallis, and H. Lal A discriminative stimulus produced by 1-(3-chlorophenyl)-piperazine (mCPP) as a putative animal model of anxiety Prog Neuropsychopharmacol Biol Psychiatry 22 1988 547 565
66. M.M. Weissman, R.C. Bland, G.J. Canino, S. Greenwald, H.G. Hwu, and C.K. Lee The cross national epidemiology of obsessive compulsive disorder. The Cross National Collaborative Group J Clin Psychiatry 55 1994 5 10
67. S.S. Winkler, B.A. Zimmer, J.C. Jackson, L.V. Kim, and D.S. Kreiss mCPP-induced ritualistic chewing behaviors in rats as related to a putative animal model of Obsessive Compulsive Disorder Program No. 741.1. 2006 Neuroscience Meeting Planner 2006 Society for Neuroscience Washington, DC Online
68. A. Woods, C. Smith, M. Szewczak, R.W. Dunn, M. Cornfeldt, and R. Corbett Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder Psychopharmacology 112 1993 195 198
69. M. Yamauchi, T. Tatebayashi, K. Nagase, M. Kojima, and T. Imanishi Chronic treatment with fluvoxamine desensitizes 5-HT2C receptor-mediated hypolocomotion in rats Pharmacol Biochem Behav 78 2004 683 689
70. J. Zohar, and T.R. Insel Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology Biol Psychiatry 22 1987 667 687
71. J. Zohar, T.R. Insel, R.C. Zohar-Kadouch, J.L. Hill, and D.L. Murphy Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment Arch Gen Psychiatry 45 1988 167 172